Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

Novavax’s COVID-19 vaccine granted full marketing authorisation in EU

The EC’s decision was supported by positive results from a phase 3 trial evaluating Nuvaxovid

- PMLiVE

Communiqué 2023: a celebration of excellence in healthcare communications

This year’s Awards, held at the London Grosvenor House Hotel, included 31 categories

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug granted full FDA approval

Leqembi was granted accelerated approval earlier this year for patients with early Alzheimer's disease

- PMLiVE

LifeArc launches rare disease programme with £100m investment

An initial £40m will go towards the creation of up to five rare disease research centres

Omnichannel

Going beyond the buzzword: omnichannel and healthcare marketing

The concept of omnichannel often gets confused with multichannel, with many pharma companies believing they are operating omnichannel when in fact it is a multichannel approach. In our latest blog,...

IGNIFI

How to Increase Engagement During Virtual Events

Tip #4 - How do you plan the agenda for your virtual event? We suggest to invite participant input to build and personalize the engagement. Check out our full top...

Impetus Digital

- PMLiVE

Takeda and F-star announce immunotherapy partnership worth over $1bn

Both companies will research and develop antibodies for new immuno-oncology targets

- PMLiVE

Horizon shares positive results for Uplizna in neuromyelitis optica spectrum disorder

The rare and debilitating disease affects approximately one to ten per 100,000 people

- PMLiVE

Galderma’s nemolizumab shows promise in phase 3 prurigo nodularis trial

The condition affects more than 70 out of every 100,000 adults aged 18 to 64 years in the US

- PMLiVE

The launch landscape

Navigating the evolving early commercialisation and launch landscape: eight powerful opportunities

Empowering Employees: Unleashing Potential for a Bright Future

We believe that true empowerment is not just giving a person a voice, but the freedom and ability to act.

Page & Page Health

- PMLiVE

FDA declines to approve Amneal Pharmaceuticals’ Parkinson’s disease treatment

The regulator said the safety for one of the drug's ingredients had not been adequately established

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links